SCHEMBL3968950

SCHEMBL3968950

CCc1nc2c(C[O])cccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDAH1 O94760 1/20 0.50
CHEK1 O14757 1/20 0.42
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GLA P06280 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
HTR6 P50406 2/20 0.37
GAA P10253 2/20 0.37
HTT P42858 1/20 0.37
DAO P14920 2/20 0.36
DDO Q99489 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
TP53 P04637 1/20 0.36
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899660 0.91 DDAH1 (0.55) DDAH1CHEK1ADORA3ADORA2AADORA1
SCHEMBL3973661 0.83 GRIN2B (0.36) CHEK1HTR6GAAHTTSMN1; SMN2
SCHEMBL6681270 0.80 CHEK1 (0.45) DDAH1CHEK1ALDH1A1HTR6DAO
SCHEMBL6582523 0.80 DDAH1 (0.42) DDAH1CHEK1ALDH1A1HTR6HTT
SCHEMBL4191637 0.79 PARP1 (0.53) ALDH1A1HTTSMN1; SMN2KDM4EATP4A
SCHEMBL4919548 0.77 DDAH1 (0.55) DDAH1ALDH1A1GAA
SCHEMBL30518181 0.77 DDAH1 (0.55) DDAH1ALDH1A1GAA
SCHEMBL8169941 0.76 POLB (0.46)
SCHEMBL1918622 0.76 DDAH1 (0.53) DDAH1CHEK1ADORA3ADORA2AADORA1
SCHEMBL3971847 0.76 DDAH1 (0.53) DDAH1CHEK1ADORA3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 DDAH1 710/4885CHEK1 4379/4885ADORA3 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.